IFM Investors Pty Ltd Sells 3,427 Shares of Danaher Co. (NYSE:DHR)

IFM Investors Pty Ltd decreased its position in shares of Danaher Co. (NYSE:DHR) by 2.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 147,142 shares of the conglomerate’s stock after selling 3,427 shares during the period. IFM Investors Pty Ltd’s holdings in Danaher were worth $40,908,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Bogart Wealth LLC increased its stake in shares of Danaher by 1.3% in the 3rd quarter. Bogart Wealth LLC now owns 33,765 shares of the conglomerate’s stock worth $9,387,000 after acquiring an additional 440 shares in the last quarter. Greystone Financial Group LLC grew its stake in shares of Danaher by 8.2% in the third quarter. Greystone Financial Group LLC now owns 34,367 shares of the conglomerate’s stock worth $9,555,000 after acquiring an additional 2,614 shares during the period. Global Assets Advisory LLC bought a new stake in Danaher during the third quarter valued at approximately $205,000. Grey Fox Wealth Advisors LLC grew its position in Danaher by 2.7% during the third quarter. Grey Fox Wealth Advisors LLC now owns 1,957 shares of the conglomerate’s stock valued at $545,000 after buying an additional 52 shares during the period. Finally, Patrick M Sweeney & Associates Inc. grew its position in Danaher by 5.1% during the third quarter. Patrick M Sweeney & Associates Inc. now owns 1,293 shares of the conglomerate’s stock valued at $360,000 after buying an additional 63 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on DHR shares. Bank of America lifted their price target on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. TD Cowen upped their price target on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday. Wells Fargo & Company assumed coverage on shares of Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price objective on the stock. Stifel Nicolaus boosted their price objective on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday. Finally, The Goldman Sachs Group upped their price target on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $287.28.

Insider Buying and Selling

In related news, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $8,229,254.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,059 shares of company stock worth $8,400,897. 11.10% of the stock is owned by company insiders.

Danaher Stock Performance

Shares of Danaher stock traded down $4.80 during midday trading on Thursday, hitting $251.20. The company had a trading volume of 1,311,761 shares, compared to its average volume of 2,727,719. The stock has a market cap of $186.06 billion, a price-to-earnings ratio of 42.65, a PEG ratio of 4.49 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The company has a fifty day simple moving average of $270.43 and a 200 day simple moving average of $260.43. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. Danaher’s revenue was up 3.1% on a year-over-year basis. During the same period last year, the firm posted $2.02 EPS. As a group, analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.43%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.